Although the IRE1 inhibitor was inefficient alone, its combination with paclitaxel delayed the time to tumor regrowth after stopping the treatment (Marciniak et al. 2022; Raymundo et al. 2020). The gene discussed is ERN1; the disease is neoplasm.